Related Experiment Video
Updated: Feb 22, 2026
09:35
A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia
Published on: November 15, 2024
935
Antidiabetic drugs and stroke risk. Current evidence
Luis Castilla-Guerra1, María Del Carmen Fernandez-Moreno2, David Leon-Jimenez1
1Department of Internal Medicine, Hospital Virgen Macarena, University of Seville, Seville, Spain.
European Journal of Internal Medicine
|September 24, 2017
Summary
Certain new antidiabetic medications, including metformin, pioglitazone, and semaglutide, can help prevent strokes in type 2 diabetes patients. These drugs offer a dual benefit of blood glucose control and cardiovascular protection.
Area of Science:
- Endocrinology
- Cardiology
- Neurology
Background:
- Cardiovascular disease (CVD) is a leading cause of death in type 2 diabetes (T2D) patients.
- T2D patients have double the risk of stroke compared to the general population.
- Traditional glucose-lowering drugs have not demonstrated stroke prevention benefits, and some increase CVD risk.
Purpose of the Study:
- To review evidence on the stroke risk associated with non-insulin antidiabetic agents.
- To identify new antidiabetic agents with potential protective effects against stroke in T2D patients.
Main Methods:
- Systematic review of existing literature.
- Analysis of clinical trial data and observational studies.
- Evaluation of stroke risk in patients using various non-insulin antidiabetic agents.
Main Results:
- Metformin, pioglitazone, and semaglutide have demonstrated a reduction in stroke risk.
- These agents provide benefits beyond glycemic control.
- Emerging data suggests promising cardiovascular risk reduction with newer antidiabetic treatments.
Conclusions:
- Metformin, pioglitazone, and semaglutide are associated with reduced stroke risk in T2D.
- These medications offer a dual approach to managing T2D by controlling blood glucose and mitigating stroke risk.
- Further research will refine treatment selection for optimal stroke risk reduction in T2D.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
720
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
720
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
621
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
621
01:06Oral Hypoglycemic Agents: Glinides
744
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
744
01:23Dipeptidyl Peptidase 4 Inhibitors
759
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
759
01:15Diabetes: Management and Pharmacotherapy
1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
01:22Diabetes Mellitus: Type 2 and Gestational
5.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.2K